{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:31:06Z","timestamp":1759159866971,"version":"3.37.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Antimicrobial-resistant<jats:italic>Neisseria gonorrhoeae<\/jats:italic>is an emerging public health problem as a result of the alarming limitation in treatment options. We examined an outbreak in California of fluoroquinolone-resistant<jats:italic>Neisseria gonorrhoeae<\/jats:italic>(QRNG) by evaluation of a combination of routine isolates from the Gonococcal Isolate Surveillance Project and isolates collected by expanded surveillance performed between April 2000 and June 2002. QRNG isolates were characterized by two methods: (i) determination of a combination of antibiogram, auxotype, serovar, Lip type, and patterns of amino acid alteration in the quinolone resistance-determining region of GyrA and ParC (ASLGP) and (ii) pulsed-field gel electrophoresis (PFGE). Strain typing was used to describe the QRNG outbreak strains and the associated antimicrobial resistance profiles. Among 79 isolates that were completely characterized, we identified 20 different ASLGP strain types, and 2 of the types were considered to belong to outbreak strains that comprised 65% (51\/79) of the isolates. By PFGE typing, there were 24 different strain types, and 4 of these were considered outbreak types and comprised 66% (52\/79) of the isolates. The overall agreement between the typing methods in distinguishing outbreak strains and non-outbreak strains was 84% (66\/79). The most common QRNG ASLGP strain type had chromosomally mediated resistance to penicillin and tetracycline and an azithromycin MIC of 0.5 \u03bcg\/ml. The occurrence of an outbreak caused by QRNG strains that could fail to be eradicated by most antibiotic classes reinforces the serious problem with antimicrobial resistance in<jats:italic>Neisseria gonorrhoeae<\/jats:italic>that the public health system faces. Adherence to a regimen with the recommended antibiotics at the appropriate dose is critical, and monitoring for antimicrobial susceptibility needs to be actively maintained to adapt treatment guidelines appropriately.<\/jats:p>","DOI":"10.1128\/jcm.01001-09","type":"journal-article","created":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T01:43:30Z","timestamp":1248313410000},"page":"2944-2949","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Strain Typing and Antimicrobial Resistance of Fluoroquinolone-Resistant<i>Neisseria gonorrhoeae<\/i>Causing a California Infection Outbreak"],"prefix":"10.1128","volume":"47","author":[{"given":"Sheldon R.","family":"Morris","sequence":"first","affiliation":[{"name":"California Department of Health Services, Sexually Transmitted Diseases Control Branch, Richmond, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas F.","family":"Moore","sequence":"additional","affiliation":[{"name":"Orange County Public Health Laboratory, Santa Ana, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Hannah","sequence":"additional","affiliation":[{"name":"Orange County Public Health Laboratory, Santa Ana, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan A.","family":"Wang","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Orange County Public Health Laboratory, Santa Ana, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Trees","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Bolan","sequence":"additional","affiliation":[{"name":"California Department of Health Services, Sexually Transmitted Diseases Control Branch, Richmond, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"California Department of Health Services, Sexually Transmitted Diseases Control Branch, Richmond, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/432801"},{"key":"e_1_3_2_3_2","unstructured":"Sexually transmitted diseases in California 2005. 2006"},{"key":"e_1_3_2_4_2","unstructured":"California gonorrhea treatment guidelines. 2006"},{"key":"e_1_3_2_5_2","first-page":"435","volume":"57","year":"2008","unstructured":"Centers for Disease Control and Prevention. 2008. Availability of cefixime 400 mg tablets\u2014United States, April 2008. MMWR Morb. Mortal. Wkly. Rep.57:435.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_6_2","first-page":"833","volume":"49","year":"2000","unstructured":"Centers for Disease Control and Prevention. 2000. Fluoroquinolone-resistance in Neisseria gonorrhoeae, Hawaii, 1999, and decreased susceptibility to azithromycin in N. gonorrhoeae, Missouri, 1999. MMWR Morb. Mortal. Wkly. Rep.49:833-837.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_7_2","first-page":"222","volume":"56","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Increases in gonorrhea\u2014eight western states, 2000-2005. MMWR Morb. Mortal. Wkly. Rep.56:222-225.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_8_2","first-page":"370","volume":"55","year":"2006","unstructured":"Centers for Disease Control and Prevention. 2006. Notice to readers: discontinuation of spectinomycin. MMWR Morb. Mortal. Wkly. Rep.55:370.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_9_2","unstructured":"PulseNet BioNumerice version 2.5 training manual. 2003"},{"key":"e_1_3_2_10_2","first-page":"42","volume":"55","year":"2006","unstructured":"Centers for Disease Control and Prevention. 2006. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recommend. Rep.55(No. RR-11):42-49.","journal-title":"MMWR Recommend. Rep."},{"key":"e_1_3_2_11_2","first-page":"332","volume":"56","year":"2007","unstructured":"Centers for Disease Control and Prevention. 2007. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb. Mortal. Wkly. Rep.56:332-336.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_12_2","unstructured":"Performance standards for antimicrobial susceptibility testing 2008"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000216012.83990.bd"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/107662903322762789"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2442"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198701000-00006"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/150.1.44"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.OLQ.0000109514.91508.FC"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.030163"},{"key":"e_1_3_2_20_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 1993"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200212000-00008"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.080222"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450110059027"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.6.3.244-248.1977"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200305000-00012"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.081721"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/430787"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-199811000-00002"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.8.2914-2916.2000"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-2-200707170-00006"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/377500"},{"key":"e_1_3_2_32_2","unstructured":"Antimicrobial resistance and implications for the twenty-first century 2008"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198810000-00006"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-8-200804150-00005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.10.2439"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.2.455"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3201\/eid1308.060948","volume":"13","year":"2007","unstructured":"Yokoi, S., T. Deguchi, T. Ozawa, M. Yasuda, S. Ito, Y. Kubota, M. Tamaki, and S. Maeda. 2007. Threat to cefixime treatment for gonorrhea. Emerg. Infect. Dis.13:1275-1277.","journal-title":"Emerg. Infect. Dis."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01001-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01001-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T09:38:01Z","timestamp":1739266681000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01001-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1128\/JCM.01001-09"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01001-09","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"type":"print","value":"0095-1137"},{"type":"electronic","value":"1098-660X"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"2009-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}